HIGHLIGHTS
- who: Shen Lin and collaborators from the NewYork-Presbyterian, United States Cairo University, Egypt have published the research: The Predictive Value of PD-L1 Expression Level in Evaluating the Cost-Effectiveness of Atezolizumab/Pembrolizumab, in the Journal: (JOURNAL)
- what: This study evaluated the cost-effectiveness of atezolizumab and pembrolizumab in comparison with chemotherapy in previously untreated stage IV NSCLC patients, and further sub-analyzed the cost-effectiveness in different PD-L1 expression levels (u226550% and u22651%). This study has some strengths, the notable one being the indirect comparison of two ICIs based on the different . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.